Clinical Trials
13 trialsNCT07165132 2026-04-13
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Phase 1 Recruiting
NCT00986661 2022-11-02
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
Phase 1 Unknown
NCT00446082 2020-12-21
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Novartis
Phase 1 Completed
NCT01263353 2020-12-21
COOPERATE-1
Novartis
Phase 1 Completed
NCT01165658 2020-01-02
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03057509 2019-06-21
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Phase 1 Withdrawn
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02359500 2017-05-03
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT00804336 2016-10-19
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00580320 2016-08-18
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Virginia Commonwealth University
Phase 1 Completed
NCT00942682 2014-04-29
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00339131 2011-10-12
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Molecular Insight Pharmaceuticals, Inc.
Phase 1 Completed
NCT00314925 2010-02-25
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Neotropix
Phase 1 Unknown